Protein kinase C isotypes in human erythroleukemia cell proliferation and differentiation

B. A. Hocevar, D. M. Morrow, M. L. Tykocinski, Alan P Fields

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

The human erythroleukemia (K562) cell line is induced to differentiate into megakaryocytic cells by treatment with the tumor promoter phorbol myristate acetate (PMA). PMA-induced differentiation is characterized by (1) almost complete cessation of cellular proliferation, (2) expression of the megakaryocytic cell surface marker glycoprotein IIb/IIIa (gpIIla), (3) increased secretion of granulocyte/macrophage-colony stimulating factor (GM-CSF) and (4) increased secretion of interleukin-6 (1L-6). PMA-induced differentiation is dose-dependent with maximal activity seen at 10 nM PMA. In contrast, bryostatin (bryo), a structurally distinct protein kinase C (PKC) activator, fails to induce megakaryocytic differentiation or growth arrest at the concentrations tested (0.01-100 nM). Rather, bryo inhibits PMA-induced growth arrest and megakaryocytic differentiation in a dose-dependent fashion (full inhibition at 100 nM). The divergent biological effects of PMA and bryo correspond to the differential activation and translocation of PKC isotypes in K562 cells. PKC isotype analysis demonstrates that undifferentiated cells express both α and β(II) PKC but no detectable β(I), γ or ε PKC. Treatment of cells with either PMA or bryo leads to rapid translocation of both α and β(II) PKC from the cytosol to the non-nuclear particulate fraction. However, bryo also induces selective translocation of β(II) PKC to the nuclear membrane. Nuclear β(II) PKC is functionally active as evidenced by the time-dependent phosphorylation of lamin B, a previously identified nuclear PKC substrate. These data indicate that the divergent effects of PMA and bryo on erythroleukemia cell proliferation and differentiation correspond to differential activation of β(II) PKC at the nuclear membrane. Nuclear activation of β(II) PKC by bryo appears to generate a dominant, proliferative signal that overrides the PMA-induced differentiation signal. Therefore, the α and β(II) PKC isotypes exhibit distinct translocation and activation profiles during megakaryocytic differentiation and proliferation, indicating that they play distinct roles in these cellular processes.

Original languageEnglish (US)
Pages (from-to)671-679
Number of pages9
JournalJournal of Cell Science
Volume101
Issue number3
StatePublished - 1992
Externally publishedYes

Fingerprint

Leukemia, Erythroblastic, Acute
Protein Kinase C
Bryostatins
Cell Differentiation
Tetradecanoylphorbol Acetate
Cell Proliferation
K562 Cells
Nuclear Envelope
Nuclear Proteins
Lamin Type B
Platelet Glycoprotein GPIIb-IIIa Complex
Membrane Glycoproteins
Granulocyte-Macrophage Colony-Stimulating Factor
Growth
Carcinogens
Cytosol
Interleukin-6

Keywords

  • Bryostatin 1
  • Lamin B phosphorylation
  • Nuclear protein kinase C

ASJC Scopus subject areas

  • Cell Biology

Cite this

Protein kinase C isotypes in human erythroleukemia cell proliferation and differentiation. / Hocevar, B. A.; Morrow, D. M.; Tykocinski, M. L.; Fields, Alan P.

In: Journal of Cell Science, Vol. 101, No. 3, 1992, p. 671-679.

Research output: Contribution to journalArticle

Hocevar, B. A. ; Morrow, D. M. ; Tykocinski, M. L. ; Fields, Alan P. / Protein kinase C isotypes in human erythroleukemia cell proliferation and differentiation. In: Journal of Cell Science. 1992 ; Vol. 101, No. 3. pp. 671-679.
@article{52f6f1fd5d07498996c0cd693311744d,
title = "Protein kinase C isotypes in human erythroleukemia cell proliferation and differentiation",
abstract = "The human erythroleukemia (K562) cell line is induced to differentiate into megakaryocytic cells by treatment with the tumor promoter phorbol myristate acetate (PMA). PMA-induced differentiation is characterized by (1) almost complete cessation of cellular proliferation, (2) expression of the megakaryocytic cell surface marker glycoprotein IIb/IIIa (gpIIla), (3) increased secretion of granulocyte/macrophage-colony stimulating factor (GM-CSF) and (4) increased secretion of interleukin-6 (1L-6). PMA-induced differentiation is dose-dependent with maximal activity seen at 10 nM PMA. In contrast, bryostatin (bryo), a structurally distinct protein kinase C (PKC) activator, fails to induce megakaryocytic differentiation or growth arrest at the concentrations tested (0.01-100 nM). Rather, bryo inhibits PMA-induced growth arrest and megakaryocytic differentiation in a dose-dependent fashion (full inhibition at 100 nM). The divergent biological effects of PMA and bryo correspond to the differential activation and translocation of PKC isotypes in K562 cells. PKC isotype analysis demonstrates that undifferentiated cells express both α and β(II) PKC but no detectable β(I), γ or ε PKC. Treatment of cells with either PMA or bryo leads to rapid translocation of both α and β(II) PKC from the cytosol to the non-nuclear particulate fraction. However, bryo also induces selective translocation of β(II) PKC to the nuclear membrane. Nuclear β(II) PKC is functionally active as evidenced by the time-dependent phosphorylation of lamin B, a previously identified nuclear PKC substrate. These data indicate that the divergent effects of PMA and bryo on erythroleukemia cell proliferation and differentiation correspond to differential activation of β(II) PKC at the nuclear membrane. Nuclear activation of β(II) PKC by bryo appears to generate a dominant, proliferative signal that overrides the PMA-induced differentiation signal. Therefore, the α and β(II) PKC isotypes exhibit distinct translocation and activation profiles during megakaryocytic differentiation and proliferation, indicating that they play distinct roles in these cellular processes.",
keywords = "Bryostatin 1, Lamin B phosphorylation, Nuclear protein kinase C",
author = "Hocevar, {B. A.} and Morrow, {D. M.} and Tykocinski, {M. L.} and Fields, {Alan P}",
year = "1992",
language = "English (US)",
volume = "101",
pages = "671--679",
journal = "Journal of Cell Science",
issn = "0021-9533",
publisher = "Company of Biologists Ltd",
number = "3",

}

TY - JOUR

T1 - Protein kinase C isotypes in human erythroleukemia cell proliferation and differentiation

AU - Hocevar, B. A.

AU - Morrow, D. M.

AU - Tykocinski, M. L.

AU - Fields, Alan P

PY - 1992

Y1 - 1992

N2 - The human erythroleukemia (K562) cell line is induced to differentiate into megakaryocytic cells by treatment with the tumor promoter phorbol myristate acetate (PMA). PMA-induced differentiation is characterized by (1) almost complete cessation of cellular proliferation, (2) expression of the megakaryocytic cell surface marker glycoprotein IIb/IIIa (gpIIla), (3) increased secretion of granulocyte/macrophage-colony stimulating factor (GM-CSF) and (4) increased secretion of interleukin-6 (1L-6). PMA-induced differentiation is dose-dependent with maximal activity seen at 10 nM PMA. In contrast, bryostatin (bryo), a structurally distinct protein kinase C (PKC) activator, fails to induce megakaryocytic differentiation or growth arrest at the concentrations tested (0.01-100 nM). Rather, bryo inhibits PMA-induced growth arrest and megakaryocytic differentiation in a dose-dependent fashion (full inhibition at 100 nM). The divergent biological effects of PMA and bryo correspond to the differential activation and translocation of PKC isotypes in K562 cells. PKC isotype analysis demonstrates that undifferentiated cells express both α and β(II) PKC but no detectable β(I), γ or ε PKC. Treatment of cells with either PMA or bryo leads to rapid translocation of both α and β(II) PKC from the cytosol to the non-nuclear particulate fraction. However, bryo also induces selective translocation of β(II) PKC to the nuclear membrane. Nuclear β(II) PKC is functionally active as evidenced by the time-dependent phosphorylation of lamin B, a previously identified nuclear PKC substrate. These data indicate that the divergent effects of PMA and bryo on erythroleukemia cell proliferation and differentiation correspond to differential activation of β(II) PKC at the nuclear membrane. Nuclear activation of β(II) PKC by bryo appears to generate a dominant, proliferative signal that overrides the PMA-induced differentiation signal. Therefore, the α and β(II) PKC isotypes exhibit distinct translocation and activation profiles during megakaryocytic differentiation and proliferation, indicating that they play distinct roles in these cellular processes.

AB - The human erythroleukemia (K562) cell line is induced to differentiate into megakaryocytic cells by treatment with the tumor promoter phorbol myristate acetate (PMA). PMA-induced differentiation is characterized by (1) almost complete cessation of cellular proliferation, (2) expression of the megakaryocytic cell surface marker glycoprotein IIb/IIIa (gpIIla), (3) increased secretion of granulocyte/macrophage-colony stimulating factor (GM-CSF) and (4) increased secretion of interleukin-6 (1L-6). PMA-induced differentiation is dose-dependent with maximal activity seen at 10 nM PMA. In contrast, bryostatin (bryo), a structurally distinct protein kinase C (PKC) activator, fails to induce megakaryocytic differentiation or growth arrest at the concentrations tested (0.01-100 nM). Rather, bryo inhibits PMA-induced growth arrest and megakaryocytic differentiation in a dose-dependent fashion (full inhibition at 100 nM). The divergent biological effects of PMA and bryo correspond to the differential activation and translocation of PKC isotypes in K562 cells. PKC isotype analysis demonstrates that undifferentiated cells express both α and β(II) PKC but no detectable β(I), γ or ε PKC. Treatment of cells with either PMA or bryo leads to rapid translocation of both α and β(II) PKC from the cytosol to the non-nuclear particulate fraction. However, bryo also induces selective translocation of β(II) PKC to the nuclear membrane. Nuclear β(II) PKC is functionally active as evidenced by the time-dependent phosphorylation of lamin B, a previously identified nuclear PKC substrate. These data indicate that the divergent effects of PMA and bryo on erythroleukemia cell proliferation and differentiation correspond to differential activation of β(II) PKC at the nuclear membrane. Nuclear activation of β(II) PKC by bryo appears to generate a dominant, proliferative signal that overrides the PMA-induced differentiation signal. Therefore, the α and β(II) PKC isotypes exhibit distinct translocation and activation profiles during megakaryocytic differentiation and proliferation, indicating that they play distinct roles in these cellular processes.

KW - Bryostatin 1

KW - Lamin B phosphorylation

KW - Nuclear protein kinase C

UR - http://www.scopus.com/inward/record.url?scp=0026510349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026510349&partnerID=8YFLogxK

M3 - Article

C2 - 1522149

AN - SCOPUS:0026510349

VL - 101

SP - 671

EP - 679

JO - Journal of Cell Science

JF - Journal of Cell Science

SN - 0021-9533

IS - 3

ER -